HKSE - Delayed Quote HKD

Yunkang Group Limited (2325.HK)

Compare
7.550 +0.070 (+0.94%)
At close: December 27 at 9:48:47 AM GMT+8
Loading Chart for 2325.HK
DELL
  • Previous Close 7.480
  • Open 7.600
  • Bid 7.380 x --
  • Ask 7.550 x --
  • Day's Range 7.600 - 7.600
  • 52 Week Range 6.000 - 12.300
  • Volume 2,000
  • Avg. Volume 132,024
  • Market Cap (intraday) 4.518B
  • Beta (5Y Monthly) -0.34
  • PE Ratio (TTM) --
  • EPS (TTM) -0.490
  • Earnings Date --
  • Forward Dividend & Yield 0.02 (0.26%)
  • Ex-Dividend Date Jul 4, 2024
  • 1y Target Est 12.50

Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus, and nucleic acid tests for respiratory pathogens; genetic reproduction, and screening tests. In addition, the company offers routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. Further, it provides diagnostic testing services for financial institutions and insurance companies, including personalized diagnostic testing, medical report consultation, and hospital referral services; information technology, medical logistics, and medical equipment procurement; and healthcare technology development. The company provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China.

www.yunkanghealth.com

1,459

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 2325.HK

View More

Performance Overview: 2325.HK

Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

2325.HK
38.50%
HANG SENG INDEX
17.85%

1-Year Return

2325.HK
34.22%
HANG SENG INDEX
22.95%

3-Year Return

2325.HK
4.31%
HANG SENG INDEX
13.49%

5-Year Return

2325.HK
4.31%
HANG SENG INDEX
27.90%

Compare To: 2325.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2325.HK

View More

Valuation Measures

As of 12/27/2024
  • Market Cap

    4.52B

  • Enterprise Value

    4.28B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.37

  • Price/Book (mrq)

    2.21

  • Enterprise Value/Revenue

    5.06

  • Enterprise Value/EBITDA

    189.17

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -34.87%

  • Return on Assets (ttm)

    -3.43%

  • Return on Equity (ttm)

    -13.11%

  • Revenue (ttm)

    794.58M

  • Net Income Avi to Common (ttm)

    -277.1M

  • Diluted EPS (ttm)

    -0.490

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.7B

  • Total Debt/Equity (mrq)

    61.15%

  • Levered Free Cash Flow (ttm)

    -58.96M

Research Analysis: 2325.HK

View More

People Also Watch